Psychiatric Outcomes after GLP-1 Receptor Agonists versus Metformin in Hidradenitis Suppurativa.

Authors

Raslina Shrestha, Hue T T Tran, Jun Ma, Duc L Van, David A Wetter, Rozalina G McCoy, Giang H Nguyen

Published in

Skin appendage disorders. Apr 24, 2026. Epub Apr 24, 2026.

Abstract

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease associated with obesity and a high burden of psychiatric comorbidity. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and metformin are commonly prescribed for metabolic disease and have anti-inflammatory effects, prompting interest in their use among patients with HS. However, recent reports have raised concerns regarding potential psychiatric adverse effects of GLP-1RAs. We evaluated psychiatric outcomes following GLP-1RA versus metformin initiation among adults with HS.
We conducted a retrospective cohort study within the NIH All of Us Research Program (Controlled Tier v8) using a new-user, active-comparator design. Adults with HS were identified using validated SNOMED concepts. Incident users of GLP-1RAs were compared with incident users of metformin after a 365-day washout. The primary outcome was the first psychiatric diagnosis within 12 months of treatment initiation. Stabilized inverse probability of treatment weighting (IPTW) was used to control for confounding. Effect estimates included 12-month cumulative risks, risk differences (RD), risk ratios (RR), and IPTW-weighted Cox proportional hazards models.
The weighted analytic cohort included 77 GLP-1RA users and 233 metformin users. At 12 months, psychiatric diagnoses occurred in 61.3% of GLP-1RA users versus 51.1% of metformin users (RD + 10.2 percentage points; RR 1.20; 95% CI: 0.95-1.52). The hazard ratio for time to first psychiatric diagnosis was 1.26 (95% CI: 0.90-1.78). Divergence between groups occurred primarily within the first 90 days after initiation.
Among adults with HS, GLP-1RA initiation was associated with a modest, nonsignificant increase in psychiatric diagnoses compared with metformin. These findings are hypothesis-generating and warrant further investigation.

PMID:
42344960
Bibliographic data and abstract were imported from PubMed on 25 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.